Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis

Pediatric Pulmonology

Volumn 44, Issue 2, 2009, Pages 148-154

  Santos, Roberto P ^a,d   Prestidge, Claude B ^b   Brown, Michael E ^b   Urbancyzk, Brenda ^b   Murphey, Donald K ^c   Salvatore, Christine M ^a   Jafri, Hasan S ^a   McCracken Jr , George H ^a   Ahmad, Naveed ^b   Sanchez, Pablo J ^a   Siegel, Jane D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CHILDREN S MEDICAL CENTER   (United States)

^c Cook Children's Medical Center ^*  (United States)

^d ALBANY MEDICAL CENTER   (United States)

Author keywords

Genotype; Pharmacodynamics; Pharmacokinetics; Phenotype; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; ESCITALOPRAM; FLUOXETINE; LINEZOLID; SEROTONIN UPTAKE INHIBITOR; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE INCREASE; FEMALE; GENE MUTATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ACETAMIDES; ADOLESCENT; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; RETROSPECTIVE STUDIES;

EID: 59949083248     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20966     Document Type: Article

References (36)

1. CFF. Patient Registry 2005 Annual Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2005;1-20 p. Available at www.cff.org/LivingWithCF/ QualityImprovement/PatientRegistryReport
2. Miall LS, McGinley NT, Brownlee KG, Conway SP. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 2001;84:160-162.
3. Stone A, Saiman L. Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Curr Opin Pulm Med 2007;13:515-521.
4. CFF., Patient Registry 2006 Annual Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2006. Available at: www. cff.org/LivingWithCF/ QualityImprovement/PatientRegistry Report (Accessed on 4-14-08). 1-20 p.
5. Glikman D, Siegel JD, David MZ, Okoro NM, Boyle-Vavra S, Dowell ML, Daum RS. Complex molecular epidemiology of methicillin-resistant staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S aureus. Chest 2008;133:1381-1387.
6. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44:1208-1215.
7. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 -05. J. Antimicrob Chemother 2007;60:788-794.
8. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapulmonary penetration of linezolid. J. Antimicrob Chemother 2003;51:1431-1434.
9. Pfizer. Linezolid - Summary of clinical review of pediatric studies submitted in response to a written request. Ann Arbor, MI 2005; 5-18 -2006. Pfizer, Inc. Available at http://www.fda.gov/cder/foi/esum/2005/021130s009, 021131s010,021132s009-Linezolid-Clinical-BPCA.pdf
10. Rey E, Treluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998;35:313-329.
11. Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2004;48:281-284.
12. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003;42:1411-1423.
13. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmaco- kinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003;22:S153-S157.
14. Kearns GL, Abdel-Rahman SM, Blumer JL, Reed MD, James LP, Jacobs RF, Bradley JA, Welshman IR, Jungbluth GL, Stalker DJ. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000;19:1178-1184.
15. Kearns GL, Jungbluth GL, Abdel-Rahman SM, Hopkins NK, Welshman IR, Grzebyk RP, Bruss JB, Van Den Anker JN. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003;74:413-422.
16. Quesnel LB, Jaran AS, Braganza JM. Antibiotic accumulation and membrane trafficking in cystic fibrosis cells. J. Antimicrob Chemother 1998;41:215-221.
17. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl J Med 1993;328:1740-1746.
18. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N. Engl J Med 1994;331:637-642.
19. Bergeron L, Boule M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother 2005;39:956-961.
20. Pfizer, Zyvox. Accessed on May 7, 2006. Available online at http://www.pfizer.com/pfizer/download/uspi-zyvox. pdf. 2005.
21. NJMRC. Infectious Diseases Pharmacokinetics Laboratory (IDPL) at National Jewish Medical and Research Center (NJMRC). Denver, Colorado: Nationation Jewish Medical and Research Center; 2007. Available at: http://www.njc.org/ research/clinical-labs/about/learn/infectious/idpl.aspx.
22. Atkinson AJ AD, Daniels CE, Dedrick RL, Markey SP. Principles of Clinical Pharmacology. San Diego: Academic Press; 2007;11-22 p.
23. Winters ME. Basic Clinical Pharmacokinetics. Philadelphia: Lippincott Williams & Wilkins 2004.
24. Andes D, van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46:3484-3489.
25. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001;45: 1843-1846.
26. Flayhart D, Hindler JF, Bruckner DA, Hall G, Shrestha RK, Vogel SA, Richter SS, Howard W, Walther R, Carroll KC. Multicenter evaluation of BBL CHROMagar MRSA medium for direct detection of methicillin-resistant Staphylococcus aureus from surveillance cultures of the anterior nares. J. Clin Microbiol 2005; 43:5536-5540.
27. Perry JD, Davies A, Butterworth LA, Hopley AL, Nicholson A, Gould FK. Development and evaluation of a chromogenic agar medium for methicillin- resistant Staphylococcus aureus. J. Clin Microbiol 2004;42:4519-4523.
28. Gilligan PH KD, Appleman MD. In: Cystic Fibrosis Microbiology. MD A, editor. Washington, D.C: ASM Press 2006.
29. CLSI. Clinical and Laboratory Standards Institute Quality Manual. Wayne, PA: CLSI; 2006. Available at www.clsi.org.
30. Ma XX, Ito T, Tiensasitorn C, Jamklang M, Chongtrakool P, Boyle-Vavra S, Daum RS, Hiramatsu K. Novel type of staphylococcal cassette chromosome mec identified in community- acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002;46:1147-1152.
31. Kearns GL. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann Pharmacother 1993;27:74-79.
32. Susanto M, Benet LZ. Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by Pglycoprotein transport? Pharm Res 2002;19:457-462.
33. Santos RP PC, Brown ME, Urbancyzk BK, Murphey DK, Sanchez PJ, Salvatore CM, Jafri HS, McCracken GH, Siegel JD. The Use of Linezolid in Pulmonary Exacerbation Associated with Methicillin-Resistant Staphylococcus aureus (MRSA) among Children with Cystic Fibrosis (CF) (Abstract #112). 6th Annual St Jude/PIDS Pediatric Microbial Research Conference. Memphis, TN: St. Jude/PIDS Pediatric Microbial Research Conference 2007.
34. Serisier DJ, Jones G, Carroll M. Eradication of pulmonary methicillin-resistant staphylococcus aureus (MRSA) in cystic fibrosis with linezolid. J. Cyst Fibros 2004;3:61.
35. Ferrin M, Zuckerman JB, Meagher A, Blumberg EA. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr Pulmonol 2002;33:221-223.
36. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44:159-177.